Biohaven Ltd
BHVN15.110USD
+1.750+13.10%
Handelsschluss 07/17, 16:00（ET）Kurse um 15 Minuten verzögert
1.54BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biohaven Ltd Unternehmen
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Unternehmensinformationen
BörsenkürzelBHVN
Name des UnternehmensBiohaven Ltd
IPO-datumSep 23, 2022
Gegründet am2022
CEODr. Vlad Coric, M.D.
Anzahl der mitarbeiter256
WertpapierartOrdinary Share
GeschäftsjahresendeSep 23
Addresse215 Church Street
StadtNEW HAVEN
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl06510
Telefon12034040410
Websitehttps://www.biohaven.com/
BörsenkürzelBHVN
IPO-datumSep 23, 2022
Gegründet am2022
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, May 14
Aktualisiert: Wed, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
37.06%
Investment Advisor
28.02%
Hedge Fund
18.28%
Individual Investor
11.53%
Private Equity
2.88%
Research Firm
2.07%
Sovereign Wealth Fund
0.88%
Bank and Trust
0.64%
Venture Capital
0.51%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
560
104.96M
102.79%
-7.46M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.81M
4.71%
+385.00K
+8.69%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
RP Management, LLC
2.94M
2.88%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
iShares Neuroscience and Healthcare ETF
2.32%
Roundhill GLP-1 & Weight Loss ETF
1.24%
Simplify Health Care ETF
1.16%
Global X Guru Index ETF
1.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Neuroscience and Mental Health ETF
0.56%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Main Thematic Innovation ETF
0.23%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil2.32%
Roundhill GLP-1 & Weight Loss ETF
Anteil1.24%
Simplify Health Care ETF
Anteil1.16%
Global X Guru Index ETF
Anteil1.15%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.85%
Tema Neuroscience and Mental Health ETF
Anteil0.56%
SPDR S&P Biotech ETF
Anteil0.45%
WisdomTree BioRevolution Fund
Anteil0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.26%
Main Thematic Innovation ETF
Anteil0.23%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
